Exicure (XCUR) AI Stock Analysis

• Market Cap: $68.23M
• Dividend Yield: N/A
• Average Volume (3M): 9.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: N/A
• EPS Growth: 76.04%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -2.59
• Shares Outstanding: 6,317,771
• 10 Day Avg. Volume: 4,747
• 30 Day Avg. Volume: 9,818
• PEG Ratio: 0.02
• Price to Book (P/B): 9.61
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -23.45
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 17.38
• Enterprise Value/Gross Profit: 642.28
• Enterprise Value/Ebitda: -1.96
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ―

Exicure's overall stock score of 47.8 reflects significant financial challenges, including ongoing losses and reliance on external funding. Technical analysis indicates bearish momentum, and the valuation highlights risks due to negative profitability. The lack of earnings call and corporate events data further limits the assessment.

Exicure Business Overview & Revenue Model

Company Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Exicure makes money primarily through the development and commercialization of its proprietary therapies derived from its spherical nucleic acid (SNA) platform. Revenue streams include research and development collaborations with pharmaceutical companies, licensing agreements, and potential milestone payments and royalties from partnered programs. Significant partnerships play a crucial role in Exicure's earnings, as they provide funding and resources to advance clinical trials and bring therapies to market. Additionally, Exicure may generate revenue from the successful commercialization of its own pipeline products, pending regulatory approvals.

Exicure Financial Statement Overview

Summary

Exicure faces significant financial challenges, including persistent losses and reliance on external financing. While there are signs of improved equity and gross profit margins, ongoing operational inefficiencies and liquidity issues keep the financial position precarious. Future growth depends on stabilizing revenues and managing costs.

Income Statement

Exicure's income statement reveals a challenging financial position characterized by consistent net losses and negative EBIT margins. Despite a significant revenue increase in 2022, the company experienced a steep decline in 2023, with revenue dropping to zero. The gross profit margin turned positive in 2024, but net profit remains deeply negative, indicating ongoing financial struggles and inefficiencies in managing expenses.

Balance Sheet

The balance sheet shows moderate stability with a positive equity position and a manageable debt-to-equity ratio. The equity ratio indicates a decent capitalization level, although the company has a history of fluctuating liabilities, which could pose future risks. The increasing equity in 2024 suggests improved financial health, but the presence of significant liabilities requires careful monitoring.

Cash Flow

Exicure's cash flow statement reflects negative free cash flows, primarily driven by substantial operating cash outflows. While financing activities have provided liquidity, the reliance on external funding is evident. The operating cash flow to net income ratio suggests operational inefficiencies, and the free cash flow growth rate has been volatile, indicating potential liquidity challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
500.00K	0.00	28.83M	-483.00K	16.61M
	Gross Profit
-324.00K	-1.42M	26.97M	-2.26M	-15.48M
	EBIT
-12.23M	-15.00M	-1.83M	-62.55M	-25.44M
	EBITDA
-8.85M	-15.54M	78.00K	-60.63M	-22.65M
	Net Income Common Stockholders
-9.70M	-16.91M	-2.58M	-64.10M	-24.67M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.51M	816.00K	8.58M	39.14M	82.08M
	Total Assets
15.06M	11.58M	23.33M	64.87M	100.44M
	Total Debt
5.93M	6.67M	7.31M	14.74M	24.77M
	Net Debt
-6.57M	5.85M	-1.27M	-19.91M	-8.49M
	Total Liabilities
8.28M	8.55M	8.41M	53.64M	38.94M
	Stockholders Equity
6.77M	3.03M	14.92M	11.23M	61.51M
Cash Flow		Free Cash Flow
-2.91M	-10.36M	-35.67M	-35.79M	-42.44M
	Operating Cash Flow
-2.91M	-10.36M	-35.66M	-34.82M	-39.27M
	Investing Cash Flow
0.00	-1.08M	4.70M	43.09M	10.14M
	Financing Cash Flow
13.40M	3.67M	-3.10M	1.12M	15.13M

Exicure Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XCUR, the sentiment is Negative. The current price of 9.7 is below the 20-day moving average (MA) of 10.36, below the 50-day MA of 11.02, and above the 200-day MA of 9.51, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 43.48 is Neutral, neither overbought nor oversold. The STOCH value of 66.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XCUR.

Exicure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
CRBU	48 Neutral	$117.19M	―	-52.76%	―	-70.31%	-11.68%
XCUR	48 Neutral	$68.23M	―	-197.92%	―	―	76.04%
EPIX	46 Neutral	$75.90M	―	-23.07%	―	―	-19.93%
IMAB	45 Neutral	$193.40M	―	-22.38%	―	―	―
VIGL	35 Underperform	$367.77M	―	-102.70%	―	―	3.01%
UNCY	28 Underperform	$91.00M	―	-2355.27%	―	-100.00%	52.65%

Exicure Corporate Events

Exicure Secures $8.7 Million in Stock Purchase Deal

Exicure has received $8.7 million following the successful closing of a Common Stock Purchase Agreement with HiTron Systems Inc. This financial development is significant for stakeholders as it marks a substantial capital influx, which may impact the company’s operations and strategic positioning in its industry.